Simulating potential outbreaks of Delta and Omicron variants based on contact-tracing data: A modelling study in Fujian Province, China

[1]  D. Cummings,et al.  Effectiveness of an inactivated Covid-19 vaccine with homologous and heterologous boosters against Omicron in Brazil , 2022, Nature Communications.

[2]  P. Austin,et al.  Estimated Effectiveness of COVID-19 Vaccines Against Omicron or Delta Symptomatic Infection and Severe Outcomes , 2022, JAMA network open.

[3]  E. Lau,et al.  Vaccine effectiveness of one, two, and three doses of BNT162b2 and CoronaVac against COVID-19 in Hong Kong: a population-based observational study , 2022, The Lancet Infectious Diseases.

[4]  M. Ajelli,et al.  Modeling transmission of SARS-CoV-2 Omicron in China , 2022, Nature Medicine.

[5]  Ze-yu Zhao,et al.  Computing R0 of dynamic models by a definition-based method , 2022, Infectious Disease Modelling.

[6]  D. Cummings,et al.  Effectiveness of an Inactivated Covid-19 Vaccine with Homologous and Heterologous Boosters against the Omicron (B.1.1.529) Variant , 2022, medRxiv.

[7]  S. Bhatt,et al.  Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: a cohort study , 2022, The Lancet.

[8]  N. Daneman,et al.  Estimates of SARS-CoV-2 Omicron Variant Severity in Ontario, Canada. , 2022, JAMA.

[9]  S. Katikireddi,et al.  Vaccine effectiveness of heterologous CoronaVac plus BNT162b2 in Brazil , 2022, Nature medicine.

[10]  D. He,et al.  Multiple COVID-19 Waves and Vaccination Effectiveness in the United States , 2022, International journal of environmental research and public health.

[11]  Yawen Jiang,et al.  Effectiveness of Inactivated COVID-19 Vaccines Against Illness Caused by the B.1.617.2 (Delta) Variant During an Outbreak in Guangdong, China , 2022, Annals of Internal Medicine.

[12]  Wenzhou Yu,et al.  Effectiveness of Inactivated COVID-19 Vaccines Against Symptomatic, Pneumonia, and Severe Disease Caused by the Delta Variant: Real World Study and Evidence — China, 2021 , 2022, China CDC weekly.

[13]  D. Zeng,et al.  Effectiveness of Covid-19 Vaccines over a 9-Month Period in North Carolina , 2022, The New England journal of medicine.

[14]  J. Starrfelt,et al.  Reduced risk of hospitalisation among reported COVID-19 cases infected with the SARS-CoV-2 Omicron BA.1 variant compared with the Delta variant, Norway, December 2021 to January 2022 , 2022, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[15]  Tian Chen.  Feasibility of COVID-19 control from a pandemic to endemic (preprint)/ en , 2022 .

[16]  Gheyath K Nasrallah,et al.  Waning mRNA-1273 Vaccine Effectiveness against SARS-CoV-2 Infection in Qatar , 2021, medRxiv.

[17]  J. Lv,et al.  Role of asymptomatic and pre-symptomatic infections in covid-19 pandemic , 2021, BMJ.

[18]  A. Wallace,et al.  SARS-CoV-2 vaccine protection and deaths among US veterans during 2021 , 2021, Science.

[19]  Wen Zheng,et al.  COVID-19 vaccination program in the mainland of China: a subnational descriptive analysis on target population size and current progress , 2021, Infectious Diseases of Poverty.

[20]  Qun Li,et al.  Eleven COVID-19 Outbreaks with Local Transmissions Caused by the Imported SARS-CoV-2 Delta VOC — China, July–August, 2021 , 2021, China CDC weekly.

[21]  N. Ferguson,et al.  Community transmission and viral load kinetics of the SARS-CoV-2 delta (B.1.617.2) variant in vaccinated and unvaccinated individuals in the UK: a prospective, longitudinal, cohort study , 2021, The Lancet Infectious Diseases.

[22]  O. A. Ogun,et al.  Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study , 2021, The Lancet.

[23]  L. Abu-Raddad,et al.  Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar , 2021, medRxiv.

[24]  E. Undurraga,et al.  Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile , 2021, The New England journal of medicine.

[25]  L. Luo,et al.  Transmission Dynamics of an Outbreak of the COVID-19 Delta Variant B.1.617.2 — Guangdong Province, China, May–June 2021 , 2021, China CDC weekly.

[26]  A. Yılmaz,et al.  Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey , 2021, The Lancet.

[27]  M. Hassany,et al.  Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults: A Randomized Clinical Trial. , 2021, JAMA.

[28]  H. Ling,et al.  Emerging Variants of B.1.617 Lineage Identified Among Returning Chinese Employees Working in India — Chongqing Municipality, China, April 2021 , 2021, China CDC weekly.

[29]  A. Vespignani,et al.  The impact of relaxing interventions on human contact patterns and SARS-CoV-2 transmission in China , 2021, Science Advances.

[30]  A. Vespignani,et al.  Author Correction: Infectivity, susceptibility, and risk factors associated with SARS-CoV-2 transmission under intensive contact tracing in Hunan, China , 2021, Nature Communications.

[31]  D. Larremore,et al.  Model-informed COVID-19 vaccine prioritization strategies by age and serostatus , 2021, Science.

[32]  Shigui Yang,et al.  The epidemiological and radiographical characteristics of asymptomatic infections with the novel coronavirus (COVID-19): A systematic review and meta-analysis , 2021, International Journal of Infectious Diseases.

[33]  Imperial College COVID-19 Response Team,et al.  Age groups that sustain resurging COVID-19 epidemics in the United States , 2020, Science.

[34]  D. Feehan,et al.  Quantifying population contact patterns in the United States during the COVID-19 pandemic , 2020, Nature Communications.

[35]  R. Tuladhar,et al.  Asymptomatic SARS-CoV-2 Carriers: A Systematic Review and Meta-Analysis , 2021, Frontiers in Public Health.

[36]  P. Glasziou,et al.  Estimating the extent of asymptomatic COVID-19 and its potential for community transmission: Systematic review and meta-analysis. , 2020, Journal of the Association of Medical Microbiology and Infectious Disease Canada = Journal officiel de l'Association pour la microbiologie medicale et l'infectiologie Canada.

[37]  D. Larremore,et al.  Model-informed COVID-19 vaccine prioritization strategies by age and serostatus , 2020, Science.

[38]  Georgia Salanti,et al.  Occurrence and transmission potential of asymptomatic and presymptomatic SARS-CoV-2 infections: A living systematic review and meta-analysis , 2020, medRxiv.

[39]  A. Vespignani,et al.  Infectivity, susceptibility, and risk factors associated with SARS-CoV-2 transmission under intensive contact tracing in Hunan, China , 2020, medRxiv.

[40]  Jiming Zhang,et al.  Proportion of asymptomatic coronavirus disease 2019: A systematic review and meta‐analysis , 2020, Journal of medical virology.

[41]  Nuno R. Faria,et al.  Serial interval distribution of SARS-CoV-2 infection in Brazil , 2020, medRxiv.

[42]  A. Vespignani,et al.  Changes in contact patterns shape the dynamics of the COVID-19 outbreak in China , 2020, Science.

[43]  L. Meyers,et al.  Serial Interval of COVID-19 among Publicly Reported Confirmed Cases , 2020, Emerging infectious diseases.

[44]  S. Lai,et al.  Patterns of human social contact and contact with animals in Shanghai, China , 2019, Scientific Reports.

[45]  J. Wallinga,et al.  A Systematic Review of Social Contact Surveys to Inform Transmission Models of Close-contact Infections , 2018, bioRxiv.

[46]  H. Nishiura,et al.  Quantifying heterogeneous contact patterns in Japan: a social contact survey , 2019, Theoretical Biology and Medical Modelling.

[47]  D. Andersson,et al.  Efficacy and safety , 2018 .

[48]  M. Höhle.  Infectious Disease Modelling , 2016 .

[49]  K. Schillinga,et al.  A prospective longitudinal cohort study , 2011 .

[50]  Alessandra Conversi,et al.  Comparative Analysis , 2009, Encyclopedia of Database Systems.

[51]  R. Mikolajczyk,et al.  Social Contacts and Mixing Patterns Relevant to the Spread of Infectious Diseases , 2008, PLoS medicine.

[52]  J. Garland.  The New England Journal of Medicine. , 1961, Canadian Medical Association journal.